RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo offers hope for hard-to-treat lymphoma patients before transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that has returned or not responded to standard therapy. First, patients receive tafasitamab and lenalidomide, then a chemotherapy combo called ICE. The goal is to shrink or eliminate cancer before a stem …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 05:59 UTC
-
New combo therapy aims to beat back stubborn lymphoma before stem cell transplant
Disease control Recruiting nowThis study tests a new drug combination (epcoritamab plus chemotherapy) given before a stem cell transplant for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to prior treatments. The goal is to see if this approach can completely eliminate …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 05:58 UTC
-
New combo therapy aims to boost lymphoma remission after transplant
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive epcoritamab plus chemotherapy be…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
New drug may keep lymphoma in check long enough for Life-Saving cell therapy
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy in people with large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this bridging therapy can control the cancer long enough for patients to successfully unde…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to evaluate safety, the bes…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New 5-Drug cocktail ViPOR targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve co…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New combo may help more lymphoma patients qualify for potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help more people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to control the disease so patients can proceed to CAR-T, whi…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:48 UTC